Kyowa Hakko Kirin Seeks Wider Use Of Dialysis Anemia Drug
This article was originally published in PharmAsia News
Executive Summary
Japan's Kyowa Hakko Kirin applied to regulators to have its Nesp (darbepoetine) drug, now indicated for treating dialysis patients with renal anemia, also approved for cancer patients. Kyowa's application seeks approval for the drug in treating pre-dialysis patients and cancer patients who develop anemia following chemotherapy treatments. The company said it expects to get approval later this year and seesNesp as a successor to its Espo, which has a pre-dialysis indication. (Click here for more - a subscription may be required